Overview

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-20

Target enrollment:

Participant gender:

Summary

The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab